Background: The surge in the popularity of cannabis has led to an increase in the number of companies producing hemp-derived consumable cannabinoid products. Despite extensive exploration of cannabinoid efficacy, safety remains underreported. Any contaminants that are not deemed analytes of interest are ignored, leaving their identities and safety profiles a mystery. The unregulated nature of the cannabinoid market places the onus on reputable companies to set industry standards for product cleanliness. Objective: This study aimed to address this gap by assessing high and low potency forms of three popular hemp-derived cannabinoids – Delta 8-tetrahydrocannabinol (Δ8-THC), Hexahydrocannabinol (HHC), and Delta 9-tetrahydrocannabiphorol (Δ9-THCP). Methods: After identifying contaminants, the products were evaluated for toxicity in vitro using one liver and two lung cell lines in an effort to simulate the effects of oral consumption and inhalation. Results: Our study revealed that none of the compounds exhibited toxicity in the liver cell line, while all of the compounds exhibited toxicity in both of the lung cell lines – with the exception of one high-potency HHC sample. Conclusion: These findings highlight the critical need for stringent quality control in the cannabinoid industry, emphasizing the importance for both companies and consumers to prioritize clean, well-tested products to ensure safety in an increasingly unregulated market.
Read full abstract